4D Molecular Therapeutics (FDMT) Interest Coverage Ratio Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) Interest Coverage Ratio Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -347.04% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 73.00% |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - | 92.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.65% |
| Dec 31, 2025 | 116.86% |
| Sep 30, 2025 | -40.65% |
| Jun 30, 2025 | 87.07% |
| Mar 31, 2025 | 19.65% |
| Dec 31, 2024 | -36.10% |
| Sep 30, 2024 | -103.66% |
| Jun 30, 2024 | -828.79% |
| Mar 31, 2024 | -3,084.70% |
| Dec 31, 2023 | -362.62% |
| Sep 30, 2023 | 39.94% |
| Jun 30, 2023 | 69.13% |
| Mar 31, 2023 | 67.45% |
| Dec 31, 2022 | 52.01% |
| Sep 30, 2022 | -36.86% |
| Jun 30, 2022 | -122.31% |
| Mar 31, 2022 | -651.55% |
| Dec 31, 2021 | -9,712.57% |